fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

New insights into HL biology

Written by | 5 Feb 2018

Deepening understanding of the biology of Reed-Sternberg cells in Hodgkin’s lymphoma (HL) and how it relates to therapy could help predict response to PD-1 inhibition.

ASH 2017: Experts offer guidance on smouldering myeloma

Written by | 17 Jan 2018

Article written by Tom Collins. Interview by Esther Drain. Even as definitions of risk groups in myeloma become more sophisticated, a reasonable way to assess those patients with… read more.

Hesitation still surrounds use of ‘cure’ word in MM

Written by | 15 Jan 2018

Cure is not simply about having a few patients cured – it’s about reliably being able to cure a population with a disease, argues Professor S Vincent Rajkumar (Mayo Clinic,… read more.

BSH 2017: Plenary debate: Allogeneic transplantation should be considered for selected young patients

Written by | 14 Apr 2017

Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.

BSH 2017: Myeloma XI

Written by | 14 Apr 2017

Maintenance therapy with lenalidomide can improve PFS in patients with newly-diagnosed MM by almost two years compared with observation alone, in patients of all ages and all risk… read more.

BSH 2017: How I treat molecular high-risk myeloma – what can we do, what should we do?

Written by | 6 Apr 2017

High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.

BSH 2017: Are we ready to use minimum residual disease to direct therapy?

Written by | 4 Apr 2017

Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…

What does 2017 hold for myeloma patients?

Written by | 6 Feb 2017

Professor Sagar Lonial (Emory University School of Medicine),  Professor Gareth Morgan (UAMS Myeloma Institute) and Professor Graham Jackson (Newcastle) discuss what 2017 might hold for patients and the management of myeloma and… read more.

ASH 2017: Hesitation still surrounds use of ‘cure’ word in MM

Written by | 17 Jan 2017

Article written by Tom Collins. Interview by Esther Drain. With technology that allows clinicians to determine minimal residual disease negativity down to the 10-6 level, the word “cure” hangs… read more.

ESH ICMM Highlights

Written by | 3 Oct 2016

Professor Mohamad Mohty (Paris), Professor Sagar Lonial  (Atlanta) and Dr Karthik Ramasamy (Oxford) discuss their highlights from The European School of Haematology Congress on Multiple Myeloma this month. This issue covers the growing… read more.

EHA 2016: Consolidation and maintenance therapy for multiple myeloma: is it the new standard? Professor Paul Richardson (Harvard Medical School, Boston, USA) and Professor Maria-Victoria Mateos (Salamanca, Spain) discuss the meta-analysis of OS in myeloma with maintenance therapy presented at ASCO and EHA this year, along with strategies for continuous therapies

Written by | 3 Aug 2016

Consolidation and maintenance therapy for multiple myeloma: is it the new standard?   Professor Antonio Palumbo (University of Turin, Italy) and Professor Paul Richardson (Harvard Medical School, Boston,… read more.

EHA 2016: Pathophysiology and diagnosis of multiple myeloma bone disease. The chair of this year’s EHA educational session on myeloma, Professor Roman Hajek (University of Ostrava, Czech Republic), discusses highlights from the session.

Written by | 2 Aug 2016

Pathophysiology and diagnosis of multiple myeloma bone disease Evangelos Terpos, University of Athens School of Medicine, Greece Osteolytic bone disease is the most common complication of MM and… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.